What is Celestica's EBITDA?
- Celestica's annual EBITDA is $736.20M.
- Celestica's quarterly EBITDA is $187.00M.
What is EBITDA?
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a measure of a company's overall financial performance and is used as an alternative to net income in some circumstances.
How is EBITDA calculated?
EBITDA is calculated using the following formula:
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
Related Metrics
Other important metrics to assess Celestica's financial health include:
- EBITDA Ratio - measures the company's EBITDA as a percentage of its revenue:
- Annual: 7.63%
- Quarterly: 7.35%
- Growth EBITDA - measures the annual growth rate of the company's EBITDA:
- Annual: 35.43%
- Quarterly: 0.48%
- Growth EBITDA Ratio - measures the annual growth rate of the company's EBITDA ratio:
- Annual: 11.77%
- Quarterly: -1.34%
These metrics provide insights into Celestica's financial health and its ability to meet short-term obligations. Comparing these ratios with industry benchmarks can offer a deeper understanding of the company's performance.
Annual EBITDA
$736.20M
Quarterly EBITDA
$187.00M
Celestica Historical EBITDA
Historical EBITDA Ratio (Annual)
Historical EBITDA Ratio (Quarterly)
Celestica Historical EBITDA Metrics
The table below shows various financial metrics for each year, with the latest data available for the last fiscal year 2024.
| Year | EBITDA | Growth EBITDA | EBITDA Ratio | Growth EBITDA Ratio |
|---|---|---|---|---|
| 2024 | $736.20M | 35.43% | 7.63% | 11.77% |
| 2023 | $543.60M | 106.46% | 6.83% | 19.35% |
| 2022 | $263.30M | 57.01% | 5.72% | 7.00% |
| 2021 | $167.70M | 31.12% | 5.35% | 11.32% |
| 2020 | $127.90M | -14.33% | 4.80% | 23.67% |
| 2019 | $149.30M | 40.45% | 3.88% | 0.95% |
| 2018 | $106.30M | -53.30% | 3.85% | -8.17% |
| 2017 | $227.60M | -8.45% | 4.19% | -7.36% |
| 2016 | $248.60M | 35.33% | 4.52% | 16.19% |
| 2015 | $183.70M | -6.47% | 3.89% | -6.13% |
Related Metrics
Explore detailed financial metrics and analysis for CLS.